Cardinal Health, Inc. (NYSE:CAH) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totalling 10,498,346 shares, a growth of 55.4% from the June 15th total of 6,756,952 shares. Based on an average daily trading volume, of 2,700,926 shares, the short-interest ratio is currently 3.9 days. Currently, 3.3% of the shares of the stock are short sold.
In other Cardinal Health news, CEO of Cardinal Health’s pharmaceutical segment Jon L. Giacomin sold 23,270 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $72.87, for a total value of $1,695,684.90. Following the sale, the insider now owns 55,440 shares in the company, valued at $4,039,912.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.94% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. HL Financial Services LLC boosted its stake in shares of Cardinal Health by 0.3% in the first quarter. HL Financial Services LLC now owns 11,887 shares of the company’s stock valued at $969,000 after buying an additional 38 shares during the last quarter. Edmond DE Rothschild Holding S.A. boosted its stake in shares of Cardinal Health by 0.9% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 4,321 shares of the company’s stock valued at $353,000 after buying an additional 39 shares during the last quarter. Private Trust Co. NA boosted its stake in shares of Cardinal Health by 0.3% in the first quarter. Private Trust Co. NA now owns 13,731 shares of the company’s stock valued at $1,119,000 after buying an additional 41 shares during the last quarter. Alpha Windward LLC boosted its stake in shares of Cardinal Health by 1.8% in the first quarter. Alpha Windward LLC now owns 2,282 shares of the company’s stock valued at $186,000 after buying an additional 41 shares during the last quarter. Finally, Honkamp Krueger Financial Services Inc. boosted its stake in shares of Cardinal Health by 1.3% in the first quarter. Honkamp Krueger Financial Services Inc. now owns 4,575 shares of the company’s stock valued at $373,000 after buying an additional 60 shares during the last quarter. 87.52% of the stock is owned by institutional investors and hedge funds.
Shares of Cardinal Health (CAH) opened at 78.09 on Tuesday. The company has a market capitalization of $24.67 billion, a P/E ratio of 18.64 and a beta of 0.81. The firm has a 50-day moving average of $75.06 and a 200 day moving average of $76.65. Cardinal Health has a 1-year low of $62.70 and a 1-year high of $85.52.
Cardinal Health (NYSE:CAH) last announced its quarterly earnings results on Monday, May 1st. The company reported $1.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.46 by $0.07. The business had revenue of $31.82 billion during the quarter, compared to analysts’ expectations of $32.30 billion. Cardinal Health had a net margin of 1.05% and a return on equity of 25.78%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.43 EPS. On average, equities research analysts expect that Cardinal Health will post $5.35 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Saturday, July 15th. Shareholders of record on Monday, July 3rd were given a dividend of $0.4624 per share. The ex-dividend date of this dividend was Thursday, June 29th. This represents a $1.85 annualized dividend and a yield of 2.37%. This is a boost from Cardinal Health’s previous quarterly dividend of $0.45. Cardinal Health’s dividend payout ratio is presently 44.05%.
A number of brokerages have weighed in on CAH. Credit Suisse Group restated an “outperform” rating and issued a $87.00 target price (up previously from $81.00) on shares of Cardinal Health in a research report on Thursday, July 13th. BidaskClub lowered shares of Cardinal Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 11th. Evercore ISI restated an “outperform” rating on shares of Cardinal Health in a research report on Tuesday, July 4th. Zacks Investment Research lowered shares of Cardinal Health from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Finally, Vetr upgraded shares of Cardinal Health from a “hold” rating to a “buy” rating and set a $77.92 target price on the stock in a research report on Tuesday, June 13th. One investment analyst has rated the stock with a sell rating, sixteen have given a hold rating and five have assigned a buy rating to the company. Cardinal Health currently has a consensus rating of “Hold” and an average target price of $82.99.
Cardinal Health Company Profile
Cardinal Health, Inc is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also operates nuclear pharmacies and cyclotron facilities; provides pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, and provides services to healthcare companies.
What are top analysts saying about Cardinal Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cardinal Health Inc. and related companies.